Tag: Mikhail Blagosklonny

Oncotarget News

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more

PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

Oncotarget

Dr. Blagosklonny’s Battle With Cancer (Part 1)

January 22, 2024

Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.”BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail... read more

Oncotarget

Going Beyond Open-Access Publishing

March 6, 2020

The field of academic research is growing at a very fastpace, with open-access journals pioneering a new field of freely availableresearch. This type of free and accessible published... read more